MA33720B1 - Inhibiteurs peptiques cycliques de la replication du virus de l'hépatite c - Google Patents
Inhibiteurs peptiques cycliques de la replication du virus de l'hépatite cInfo
- Publication number
- MA33720B1 MA33720B1 MA34813A MA34813A MA33720B1 MA 33720 B1 MA33720 B1 MA 33720B1 MA 34813 A MA34813 A MA 34813A MA 34813 A MA34813 A MA 34813A MA 33720 B1 MA33720 B1 MA 33720B1
- Authority
- MA
- Morocco
- Prior art keywords
- hepatitis
- cyclic
- methods
- virus replication
- compounds
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title abstract 2
- 125000004122 cyclic group Chemical group 0.000 title 1
- 230000001079 digestive effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000029812 viral genome replication Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Les modes de réalisation de l'invention concernent des composés des formules générales i, ia, ii, iii, iv, v, vi-1, vi-2, vii, viii, ix, x, xi et xii, ainsi que des compositions, notamment des compositions pharmaceutiques, contenant un de ces composés. Les modes de réalisation concernent également des méthodes de traitement, notamment des méthodes de traitement d'une infection par le virus de l'hépatite c ainsi que des méthodes de traitement de la fibrose du foie, ces méthodes consistant généralement à administrer une quantité efficace d'un composé ou d'une composition selon l'invention à un individu nécessitant un tel traitement.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24646509P | 2009-09-28 | 2009-09-28 | |
| US32425110P | 2010-04-14 | 2010-04-14 | |
| US34573710P | 2010-05-18 | 2010-05-18 | |
| US34623810P | 2010-05-19 | 2010-05-19 | |
| PCT/US2010/050298 WO2011038293A1 (fr) | 2009-09-28 | 2010-09-24 | Inhibiteurs peptiques cycliques de la réplication du virus de l'hépatite c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33720B1 true MA33720B1 (fr) | 2012-11-01 |
Family
ID=43796242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34813A MA33720B1 (fr) | 2009-09-28 | 2012-04-26 | Inhibiteurs peptiques cycliques de la replication du virus de l'hépatite c |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20110081315A1 (fr) |
| EP (1) | EP2483290A4 (fr) |
| JP (1) | JP2013505952A (fr) |
| KR (1) | KR20130026410A (fr) |
| CN (2) | CN105001302A (fr) |
| AR (1) | AR078462A1 (fr) |
| AU (1) | AU2010298028A1 (fr) |
| CA (1) | CA2775697A1 (fr) |
| CO (1) | CO6531497A2 (fr) |
| EA (1) | EA201290128A1 (fr) |
| EC (1) | ECSP12011845A (fr) |
| IL (1) | IL218766A0 (fr) |
| IN (1) | IN2012DN02693A (fr) |
| MA (1) | MA33720B1 (fr) |
| MX (1) | MX2012003500A (fr) |
| PH (1) | PH12012500602A1 (fr) |
| TN (1) | TN2012000135A1 (fr) |
| TW (1) | TW201124137A (fr) |
| WO (1) | WO2011038293A1 (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2305696A3 (fr) * | 2005-07-25 | 2011-10-12 | Intermune, Inc. | Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C |
| EA200801050A1 (ru) * | 2005-10-11 | 2008-12-30 | Интермьюн, Инк. | Соединения и способы ингибирования репликации вирусного гепатита с |
| WO2009142842A2 (fr) * | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Nouveaux inhibiteurs macrocycliques de la réplication du virus de l’hépatite c |
| WO2010045266A1 (fr) * | 2008-10-15 | 2010-04-22 | Intermune, Inc. | Peptides antiviraux therapeutiques |
| TW201116540A (en) * | 2009-10-01 | 2011-05-16 | Intermune Inc | Therapeutic antiviral peptides |
| ES2586231T3 (es) * | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| EP2576564A4 (fr) * | 2010-06-07 | 2014-01-22 | Abbvie Inc | Inhibiteurs macrocyclique de la protéase à sérine du virus de l'hépatite c |
| KR101889993B1 (ko) | 2010-09-10 | 2018-08-20 | 시오노기세야쿠 가부시키가이샤 | Ampk 활성화 작용을 갖는 헤테로환 축합 이미다졸 유도체 |
| WO2012054874A1 (fr) * | 2010-10-22 | 2012-04-26 | Intermune, Inc. | Nouveaux inhibiteurs macrocycliques de la réplication du virus de l'hépatite c |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI565704B (zh) * | 2011-09-22 | 2017-01-11 | 健生醫藥公司 | 用於製備hcv巨環蛋白酶抑制劑之方法及中間物 |
| BR112014030412A2 (pt) | 2012-06-14 | 2017-06-27 | Basf Se | método para combater ou controlar pragas, método para proteger culturas, compostos, processo para a preparação de compostos, uso de um composto, composição agrícola ou veterinária e semente. |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
| EP2914613B1 (fr) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Inhibiteurs du virus de l'hépatite c |
| WO2014071007A1 (fr) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Inhibiteurs du virus de l'hépatite c |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914614B1 (fr) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Inhibiteurs du virus de l'hépatite c |
| EP2964664B1 (fr) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Inhibiteurs du virus de l'hépatite c |
| JP6511432B2 (ja) | 2013-03-15 | 2019-05-15 | ギリアード サイエンシーズ, インコーポレイテッド | C型肝炎ウイルスの大環状二環式阻害剤 |
| AR095604A1 (es) | 2013-03-15 | 2015-10-28 | Syngenta Participations Ag | Derivados de imidazopiridina útiles como microbicidas |
| WO2016127859A1 (fr) * | 2015-02-13 | 2016-08-18 | Sunshine Lake Pharma Co., Ltd. | Composés utilisés en tant qu'inhibiteurs du virus de l'hépatite c et leurs utilisations en médecine |
| CN108314648A (zh) * | 2018-04-12 | 2018-07-24 | 苏州康润医药有限公司 | 4-溴-7-氟异喹啉的合成方法 |
| CN110305018B (zh) * | 2019-06-06 | 2022-07-15 | 浙江普洛家园药业有限公司 | 一种3-溴-2-氟硝基苯的制备方法 |
| CN112358447B (zh) * | 2020-11-16 | 2022-04-12 | 苏州康润医药有限公司 | 7-氟异喹啉-1-羧酸的合成方法 |
| CN114105800B (zh) * | 2021-11-25 | 2023-09-01 | 杭州国瑞生物科技有限公司 | 一种2,3-二氨基苯甲酸甲酯的制备方法 |
| WO2025257072A1 (fr) * | 2024-06-14 | 2025-12-18 | Syngenta Crop Protection Ag | Composés de 2-oxobenzimidazole à action pesticide |
| CN119143611A (zh) * | 2024-11-15 | 2024-12-17 | 浙江大学衢州研究院 | 一种n-异丙基对氟苯胺的连续制备方法 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3547119A (en) | 1967-12-08 | 1970-12-15 | Baxter Laboratories Inc | Catheter assembly |
| US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| US3798209A (en) * | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
| US4311137A (en) | 1980-04-30 | 1982-01-19 | Sherwood Medical Industries Inc. | Infusion device |
| US4531937A (en) | 1983-01-24 | 1985-07-30 | Pacesetter Systems, Inc. | Introducer catheter apparatus and method of use |
| CS263951B1 (en) * | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
| US4755173A (en) | 1986-02-25 | 1988-07-05 | Pacesetter Infusion, Ltd. | Soft cannula subcutaneous injection set |
| US5696270A (en) | 1989-05-23 | 1997-12-09 | Abbott Laboratories | Intermediate for making retroviral protease inhibiting compounds |
| US5354866A (en) | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| GB8918806D0 (en) * | 1989-08-17 | 1989-09-27 | Shell Int Research | Chiral compounds,their preparation and use |
| US5716632A (en) | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
| DE69334250D1 (de) | 1992-12-29 | 2009-01-29 | Abbott Lab | Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern |
| US5545143A (en) | 1993-01-21 | 1996-08-13 | T. S. I. Medical | Device for subcutaneous medication delivery |
| US5624949A (en) * | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| US6693072B2 (en) * | 1994-06-02 | 2004-02-17 | Aventis Pharmaceuticals Inc. | Elastase inhibitors |
| US5756466A (en) * | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US6090822A (en) | 1995-03-03 | 2000-07-18 | Margolin; Solomon B. | Treatment of cytokine growth factor caused disorders |
| US6232333B1 (en) | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6277830B1 (en) | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
| US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| US7256005B2 (en) | 1999-08-10 | 2007-08-14 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity |
| HK1047947A1 (zh) * | 2000-04-05 | 2003-03-14 | Schering Corporation | 包含n-环状p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂 |
| AU2001253621A1 (en) * | 2000-04-19 | 2001-11-07 | Schering Corporation | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties |
| US7012066B2 (en) * | 2000-07-21 | 2006-03-14 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| MXPA03004299A (es) * | 2000-11-20 | 2004-02-12 | Bristol Myers Squibb Co | Inhibidores de tripeptido de hepatitis c. |
| CA2446380A1 (fr) * | 2001-05-08 | 2002-11-14 | Yale University | Composes proteomimetiques et procedes correspondants |
| US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| EP1497282A2 (fr) * | 2002-04-11 | 2005-01-19 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de la serine protease, notamment de la protease ns3-ns4a du virus de l'hepatite c |
| ES2315568T3 (es) * | 2002-05-20 | 2009-04-01 | Bristol-Myers Squibb Company | Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido. |
| AU2003248535A1 (en) * | 2002-05-20 | 2003-12-12 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis c virus inhibitors |
| MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| PL215228B1 (pl) * | 2002-05-20 | 2013-11-29 | Bristol Myers Squibb Co | Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie |
| PL199412B1 (pl) * | 2002-10-15 | 2008-09-30 | Boehringer Ingelheim Int | Nowe kompleksy rutenu jako (pre)katalizatory reakcji metatezy, pochodne 2-alkoksy-5-nitrostyrenu jako związki pośrednie i sposób ich wytwarzania |
| EP1615947A2 (fr) * | 2003-04-10 | 2006-01-18 | Boehringer Ingelheim International GmbH | Procede de preparation de composes macrocycliques |
| ATE422895T1 (de) * | 2003-04-16 | 2009-03-15 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
| WO2004093798A2 (fr) * | 2003-04-18 | 2004-11-04 | Enanta Pharmaceuticals, Inc. | Composes macrocycliques de quinoxalinyle inhibant les serine proteases de l'hepatite c |
| US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| NZ546663A (en) * | 2003-10-10 | 2010-01-29 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US7365092B2 (en) * | 2003-10-10 | 2008-04-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| WO2005037214A2 (fr) * | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Acylsulfonamides et acides carboxyliques macrocycliques utilises en tant qu'inhibiteurs de la replication du virus de l'hepatite c |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| US7939538B2 (en) * | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
| DE102004033312A1 (de) * | 2004-07-08 | 2006-01-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren |
| JP4914355B2 (ja) * | 2004-07-20 | 2012-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎インヒビターペプチド類似体 |
| MX2007002371A (es) * | 2004-08-27 | 2007-04-23 | Schering Corp | Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. |
| US7189844B2 (en) * | 2004-09-17 | 2007-03-13 | Boehringer Ingelheim International Gmbh | Ring-closing metathesis process in supercritical fluid |
| AU2006242475B2 (en) * | 2005-05-02 | 2011-07-07 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| US7608592B2 (en) * | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
| US7601686B2 (en) * | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI389908B (zh) * | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| AR057456A1 (es) * | 2005-07-20 | 2007-12-05 | Merck & Co Inc | Inhibidores de la proteasa ns3 del vhc |
| EP2305696A3 (fr) * | 2005-07-25 | 2011-10-12 | Intermune, Inc. | Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C |
| PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| BRPI0614637A2 (pt) * | 2005-07-29 | 2011-04-12 | Tibotec Pharm Ltd | inibidores macrocìclicos do vìrus da hepatite c |
| ES2401661T3 (es) * | 2005-08-02 | 2013-04-23 | Vertex Pharmaceuticals Incorporated | Inhibidores de serina proteasas |
| EA200801050A1 (ru) * | 2005-10-11 | 2008-12-30 | Интермьюн, Инк. | Соединения и способы ингибирования репликации вирусного гепатита с |
| US7772183B2 (en) * | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7601752B2 (en) * | 2005-11-16 | 2009-10-13 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives |
| US7728148B2 (en) * | 2006-06-06 | 2010-06-01 | Enanta Pharmaceuticals, Inc. | Acyclic oximyl hepatitis C protease inhibitors |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| WO2008008776A2 (fr) * | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Inhibiteurs du virus de l'hépatite c |
| ES2448494T3 (es) * | 2006-07-13 | 2014-03-14 | Achillion Pharmaceuticals, Inc. | Péptidos de 4-amino-4-oxobutanoilo en calidad de inhibidores de la replicación viral |
| US7635683B2 (en) * | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| US7718612B2 (en) * | 2007-08-02 | 2010-05-18 | Enanta Pharmaceuticals, Inc. | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
| US20090035267A1 (en) * | 2007-07-31 | 2009-02-05 | Moore Joel D | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors |
| CN101674844A (zh) * | 2006-08-04 | 2010-03-17 | 英安塔制药有限公司 | 四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂 |
| US7662779B2 (en) * | 2006-08-11 | 2010-02-16 | Enanta Pharmaceuticals, Inc. | Triazolyl macrocyclic hepatitis C serine protease inhibitors |
| US20080038225A1 (en) * | 2006-08-11 | 2008-02-14 | Ying Sun | Triazolyl acyclic hepatitis c serine protease inhibitors |
| US7687459B2 (en) * | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
| US20090035268A1 (en) * | 2007-08-01 | 2009-02-05 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
| US7582605B2 (en) * | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
| US7605126B2 (en) * | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
| US20090098085A1 (en) * | 2006-08-11 | 2009-04-16 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
| US20080107625A1 (en) * | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
| US8343477B2 (en) * | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) * | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008059046A1 (fr) * | 2006-11-17 | 2008-05-22 | Tibotec Pharmaceuticals Ltd. | Inhibiteurs macrocycliques du virus de l'hépatite c |
| JP2010518128A (ja) * | 2007-02-16 | 2010-05-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎ns3プロテアーゼのインヒビター |
| EP2139854A2 (fr) * | 2007-03-23 | 2010-01-06 | Schering Corporation | Inhibiteurs de cétoamides de p1 non épimérisables de protéase de ns3 du virus de l'hépatite c (vhc) |
| US20090123423A1 (en) * | 2007-04-26 | 2009-05-14 | Yonghua Gai | Hydroxyamic analogs as hepatitis c virus serine protease inhibitor |
| WO2008137779A2 (fr) | 2007-05-03 | 2008-11-13 | Intermune, Inc. | Inhibiteurs macrocycliques innovants de la réplication du virus de l'hépatite c |
| EP2152707B1 (fr) * | 2007-05-04 | 2012-06-20 | Bristol-Myers Squibb Company | Agonistes [6,5]-bicycliques du récepteur gpr119 de la protéine g |
| CA2686546A1 (fr) * | 2007-05-10 | 2008-11-20 | Intermune, Inc. | Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c |
| US20090005387A1 (en) * | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
| AR068794A1 (es) * | 2007-06-29 | 2009-12-09 | Gilead Sciences Inc | Compuestos antivirales |
| WO2009014730A1 (fr) * | 2007-07-26 | 2009-01-29 | Idenix Pharmaceuticals, Inc. | Inhibiteurs macrocycliques de la sérine protéase |
| US20090053175A1 (en) * | 2007-08-24 | 2009-02-26 | Yat Sun Or | Substitute pyrrolidine derivatives |
| US20090060874A1 (en) * | 2007-09-05 | 2009-03-05 | Yao-Ling Qiu | Bicyclic pyrrolidine derivatives |
| CA2700383A1 (fr) * | 2007-09-24 | 2009-04-02 | Achillion Pharmaceuticals, Inc. | Peptides contenant de l'uree en tant qu'inhibiteurs de la replication virale |
| US20090082366A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched telaprevir |
| KR101396696B1 (ko) * | 2007-10-10 | 2014-05-16 | 노파르티스 아게 | 스피로피롤리딘, 및 hcv 및 hiv 감염에 대한 그의 용도 |
| US20090111757A1 (en) * | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
| US8383583B2 (en) * | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| JP2011503231A (ja) * | 2007-11-20 | 2011-01-27 | コンサート ファーマシューティカルズ インコーポレイテッド | Hcv感染処置のためのペプチド |
| AU2008340430B2 (en) * | 2007-12-21 | 2013-01-24 | F. Hoffmann-La Roche Ag | Process for the preparation of a macrocycle |
| WO2009142842A2 (fr) * | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Nouveaux inhibiteurs macrocycliques de la réplication du virus de l’hépatite c |
| KR20110065440A (ko) * | 2008-07-02 | 2011-06-15 | 아이데닉스 파마슈티칼스, 인코포레이티드 | 바이러스 감염의 치료를 위한 화합물 및 제약 조성물 |
| EP2323981B1 (fr) * | 2008-08-07 | 2014-03-12 | F. Hoffmann-La Roche AG | Procédé pour la préparation d'un macrocycle |
| US7906655B2 (en) * | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| UY32099A (es) * | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| AU2009293493B2 (en) * | 2008-09-17 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Combination of HCV NS3 protease inhibitor with interferon and ribavirin |
| US8603737B2 (en) * | 2008-09-19 | 2013-12-10 | Celgene Avilomics Research, Inc. | Methods for identifying HCV protease inhibitors |
| US8563505B2 (en) * | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8044087B2 (en) * | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100080770A1 (en) * | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2010045266A1 (fr) * | 2008-10-15 | 2010-04-22 | Intermune, Inc. | Peptides antiviraux therapeutiques |
| JP5689810B2 (ja) * | 2008-11-20 | 2015-03-25 | アキリオン ファーマシューティカルズ,インコーポレーテッド | C型肝炎ウイルス用の環状カルボキサミド化合物およびその類似体 |
| US20110064694A1 (en) * | 2009-09-09 | 2011-03-17 | Yale University | Anti-hepatitis c activity of meso-tetrakis-porphyrin analogues |
| US8703938B2 (en) * | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8822700B2 (en) * | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8927709B2 (en) * | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8759332B2 (en) * | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011031904A1 (fr) * | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc | Inhibiteurs du virus de l'hépatite c |
| US8815928B2 (en) * | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| EP2477980B1 (fr) * | 2009-09-15 | 2016-06-08 | Taigen Biotechnology Co., Ltd. | Inhibiteurs de protéases de vhc |
| TW201116540A (en) * | 2009-10-01 | 2011-05-16 | Intermune Inc | Therapeutic antiviral peptides |
-
2010
- 2010-09-24 CN CN201510341151.8A patent/CN105001302A/zh active Pending
- 2010-09-24 EP EP10819571.0A patent/EP2483290A4/fr not_active Withdrawn
- 2010-09-24 PH PH1/2012/500602A patent/PH12012500602A1/en unknown
- 2010-09-24 WO PCT/US2010/050298 patent/WO2011038293A1/fr not_active Ceased
- 2010-09-24 CA CA2775697A patent/CA2775697A1/fr not_active Abandoned
- 2010-09-24 EA EA201290128A patent/EA201290128A1/ru unknown
- 2010-09-24 KR KR1020127010337A patent/KR20130026410A/ko not_active Withdrawn
- 2010-09-24 IN IN2693DEN2012 patent/IN2012DN02693A/en unknown
- 2010-09-24 CN CN201080053601.9A patent/CN102741270B/zh not_active Expired - Fee Related
- 2010-09-24 US US12/890,475 patent/US20110081315A1/en not_active Abandoned
- 2010-09-24 AU AU2010298028A patent/AU2010298028A1/en not_active Abandoned
- 2010-09-24 JP JP2012531086A patent/JP2013505952A/ja not_active Withdrawn
- 2010-09-24 MX MX2012003500A patent/MX2012003500A/es not_active Application Discontinuation
- 2010-09-28 TW TW099132976A patent/TW201124137A/zh unknown
- 2010-09-28 AR ARP100103512A patent/AR078462A1/es unknown
-
2012
- 2012-03-21 IL IL218766A patent/IL218766A0/en unknown
- 2012-03-27 TN TNP2012000135A patent/TN2012000135A1/en unknown
- 2012-04-26 MA MA34813A patent/MA33720B1/fr unknown
- 2012-04-27 EC ECSP12011845 patent/ECSP12011845A/es unknown
- 2012-04-27 CO CO12069712A patent/CO6531497A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL218766A0 (en) | 2012-06-28 |
| EP2483290A1 (fr) | 2012-08-08 |
| EA201290128A1 (ru) | 2013-01-30 |
| CN102741270A (zh) | 2012-10-17 |
| US20110081315A1 (en) | 2011-04-07 |
| JP2013505952A (ja) | 2013-02-21 |
| TW201124137A (en) | 2011-07-16 |
| KR20130026410A (en) | 2013-03-13 |
| CO6531497A2 (es) | 2012-09-28 |
| AU2010298028A1 (en) | 2012-04-19 |
| IN2012DN02693A (fr) | 2015-09-04 |
| CN102741270B (zh) | 2015-07-22 |
| TN2012000135A1 (en) | 2013-09-19 |
| WO2011038293A1 (fr) | 2011-03-31 |
| EP2483290A4 (fr) | 2013-05-01 |
| AR078462A1 (es) | 2011-11-09 |
| CA2775697A1 (fr) | 2011-03-31 |
| AU2010298028A2 (en) | 2012-10-04 |
| PH12012500602A1 (en) | 2017-08-23 |
| ECSP12011845A (es) | 2012-06-29 |
| CN105001302A (zh) | 2015-10-28 |
| MX2012003500A (es) | 2012-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31497B1 (fr) | Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c | |
| MA32225B1 (fr) | Nouveaux inhibiteurs macrocycliques de la replication du virus de l'hepatite c | |
| MA29746B1 (fr) | Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l'hepatite c | |
| MX2024003960A (es) | Compuestos antivirales que contienen nitrilo. | |
| MA31496B1 (fr) | Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c | |
| EA201290128A1 (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
| MA34013B1 (fr) | Inhibiteurs du virus de l'hépatite c | |
| EA200870216A1 (ru) | Амидо соединения и их применение в качестве лекарственных средств | |
| WO2008005511A8 (fr) | Nouveaux inhibiteurs de la réplication du virus de l'hépatite c | |
| MA34896B1 (fr) | Inhibiteurs du virus de l'hepatite c | |
| MA35459B1 (fr) | Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit | |
| MX2009000657A (es) | Composiciones y metodos para el tratamiento de mucositis. | |
| MX2012003171A (es) | Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c. | |
| PH12013500913A1 (en) | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | |
| WO2009134616A8 (fr) | Nouveaux inhibiteurs de réplication du virus de l’hépatite c | |
| TN2009000428A1 (fr) | Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
| MA32108B1 (fr) | Derives d'indazole | |
| BR112012017458A2 (pt) | uso de um agente de modificação de hormônio adrenal | |
| EA201070250A1 (ru) | Противомикробный парентеральный состав | |
| CO6612211A2 (es) | Derivado de amida que tiene una acción hipoglucémica y/o una acción protectora de células b o pancreas | |
| MX2024012970A (es) | Inhibidores de la 17-beta-hidroxiesteroide deshidrogenasa tipo 13 que contienen pirimidinona | |
| MA33979B1 (fr) | Piperazines en tant qu'agents antipaludiques | |
| MX2007011814A (es) | Compuestos citoesqueleticos activos, composiciones y usos. | |
| MX2023011057A (es) | Derivados de indolina como inhibidores de receptores de dominio de discoidina 1 (ddr1) y receptores de dominio de discoidina 2 (ddr2). | |
| DE60335810D1 (de) | Medizinische zusammensetzungen zur hemmung der expression von atp-citrat-lyase und ihre verwendung |